Gilead Sciences presented new HIV treatment and cure research at CROI 2025, showcasing advancements in long-acting therapies and investigational cure strategies. The company highlighted the long-term efficacy of Biktarvy in people with HIV and HBV coinfection, showing high viral suppression rates in a Phase 3 study.

Gilead also announced that its investigational long-acting treatment regimen, combining lenacapavir with broadly neutralizing antibodies (bNAbs), met its primary endpoint in a Phase 2 study and received Breakthrough Therapy Designation from the FDA. This twice-yearly injectable therapy demonstrated strong efficacy, with 96% of participants maintaining viral suppression at 26 weeks.

Additionally, results from the first HIV cure clinical trial conducted in South Africa were presented. The study tested a combination of investigational compounds, including vesatolimod and bNAbs, in individuals who had been virologically suppressed. While the approach did not achieve a complete cure, the findings provide insights for future cure strategies.

Gilead remains committed to developing innovative treatments for HIV, with ongoing research into long-acting therapies and potential cure approaches.